Balanced Pharma

Growth Stage

Reinventing medical and dental injections for a better patient experience

Analytics

Raised to Date: Raised: $0

Aggregate Commitments $

Platform

Dalmore Group

Start Date

04/11/2022

Close Date

04/10/2023

Min. Goal

$100

Max. Goal

$25,000,000

Min. Investment

$100

Security Type

Equity - Common

Funding Type

RegA+

Series

Seed

Price Per Share

$4.00

Pre-Money Valuation

$82,440,000

Rolling Commitments $

Status

Active

Reporting Date

05/21/2022

Days Remaining

324

% of Min. Goal

0%

% of Max. Goal

0%

Likelihood of Max
unlikely
Avg. Daily Raise

$0

Momentum
cold.svg
Log in or create a free account today to gain access to KingsCrowd analytics.
Location

Cornelius, North Carolina

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2B

Margin

Medium

Capital Intensity

Low

Business Type

Growth

Balanced Pharma is raising funds on Dalmore Group through Reg A+ crowdfunding. The company intends to develop and sell a drug named Libracaine Dental. It is a pH-balanced injectable local anesthetic to be used for dental procedures. The drug is in the development phase and will be used to save time for dentists, reduce pain for patients, and improve the patient experience. J. Scott Keadle founded Balanced Pharma in 2020. The current crowdfunding campaign has no minimum target and a maximum target of $25,000,000. The campaign proceeds will be used for product development, product manufacturing, product marketing and disease awareness, intellectual property development, and general and administrative purposes.

Balance Sheet

Cash and Cash Equivalents

$1,616,810

Investment Securities

$0

Total Investments

$0

Accounts and Notes Receivable

$0

Loans

$0

Property, Plant and Equipment (PP&E)

$0

Property and Equipment

$0

Total Assets

$1,696,346

Accounts Payable & Accrued Liabilities

$3,558

Policy Liabilities and Accruals

$0

Deposits

$0

Long Term Debt

$0

Total Liabilities

$3,588

Total Stockholders' Equity

$1,692,758

Total Liabilities and Equity

$1,696,346

Statement of Comprehensive Income Information

Total Revenues

$0

Total Interest Income

$0

Costs & Expenses Applicable to Rev

$0

Total Interest Expenses

$0

Depreciation and Amortization

$0

Net Income

$-900,980

Earnings Per Share - Basic

$0

Earnings Per Share - Diluted

$0

Auditor: Artesian CPA, LLC
Financials as of: 04/11/2022
Log in or create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Starter

$8.33 /month
billed annually
Free portfolio tracking. Limited reports and filters.
Plan Includes:
Everything in Free, plus
Advanced company search ( limited filters)
Founder profiles and exclusive webinars
2 Analyst Reports per month
Get Starter Annual

Pro

$25 /month
billed annually
Unlimited analyst reports and market analytics.
Plan Includes:
Everything in Starter, plus
Full access to all Analyst Reports
Filter on Analyst Reports (e.g. Top Deal, Deal to Watch, etc.)
Market Analytics
Get Pro Annual

Merlin

$41.67 /month
billed annually
Full site access including KingsCrowd ratings.
Plan Includes:
Everything in Pro, plus
Search and filter companies by KingsCrowd ratings
Company specific KingsCrowd rating and risk assessment
Get Merlin Annual
Already a member? Log in here.

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Balanced Pharma on Dalmore Group 2022
$
Platform: Dalmore Group
Security Type: Equity - Common
Valuation: $82,440,000

Follow company

Follow Balanced Pharma on Dalmore Group 2022
View on Dalmore Group
Bullish / Bearish
You're Bullish on Balanced Pharma on Dalmore Group 2022

Thank you for your vote on Balanced Pharma on Dalmore Group 2022

Bullish / Bearish
You're Bearish on Balanced Pharma on Dalmore Group 2022

Thank you for your vote on Balanced Pharma on Dalmore Group 2022